Key result
The 2013 Diabetes Canada guidelines dissemination was associated with a significant decrease in prescribing trends for statins and ACEI/ARBs.
Why the study?
Does the dissemination of the 2013 Diabetes Canada guidelines increase the prescription rates of vascular protective medications in patients ≥40 years with type 2 diabetes?
Cohort
Yes
Does the dissemination of the 2013 Diabetes Canada guidelines increase the prescription rates of vascular protective medications in patients ≥40 years with type 2 diabetes?
The dissemination of the 2013 Diabetes Canada guidelines did not increase the prescription of vascular protective medications, highlighting the need for more effective knowledge translation strategies in primary care.
Answers are grounded in this paper and cite their sources.
May signal unintended guideline effects on cardioprotective prescribing; leaves open questions on dissemination effectiveness.
OBJECTIVE The 2013 Diabetes Canada guidelines launched targeted dissemination tools and a simple assessment for vascular protection. We aimed to 1) examine changes associated with the launch of the 2013 guidelines and additional dissemination efforts in the rates of vascular protective medications prescribed in primary care for older patients with diabetes and 2) examine differences in the rates of prescriptions of vascular protective medications by patient and provider characteristics. RESEARCH DESIGN AND METHODS The study population included patients (≥40 years of age) from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with type 2 diabetes and at least one clinic visit from April 2010 to December 2015. An interrupted time series analysis was used to assess the proportion of eligible patients prescribed a statin, ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB), or antiplatelet prescription in each quarter. Proton pump inhibitor (PPI) prescriptions were the reference control. RESULTS A dynamic cohort was used where participants were enrolled each quarter using a prespecified set of conditions (range 25,985–70,693 per quarter). There were no significant changes in statin (P = 0.43), ACEI/ARB (P = 0.42), antiplatelet (P = 0.39), or PPI (P = 0.16) prescriptions at baseline (guideline intervention). After guideline publication, there was a significant change in slope for statin (−0.52% per quarter, SE 0.15, P < 0.05), ACEI/ARB (−0.38% per quarter, SE 0.13, P < 0.05), and reference PPI (−0.18% per quarter, SE 0.05, P < 0.05) prescriptions. CONCLUSIONS There was a decrease in prescribing trends over time that was not specific to vascular protective medications. More effective knowledge translation strategies are needed to improve vascular protection in diabetes in order for patients to receive the most effective interventions.
No takes yet. Share an insight, caveat, or question.
Rigobon et al. (2018) conducted a cohort in type 2 diabetes. 2013 Diabetes Canada guidelines dissemination vs. Pre-guideline baseline period was evaluated on Proportion of eligible patients prescribed a statin, ACEI/ARB, or antiplatelet prescription in each quarter (change in slope -0.52% per quarter for statins, p=<0.05). The 2013 Diabetes Canada guidelines dissemination was associated with a significant decrease in prescribing trends for statins and ACEI/ARBs.
Synapse has enriched 10 related papers. Consider them for comparative context: